Imaging the effect of HSP90 inhibitor AUY922 on HER2 expression by means of 89Zr-trastuzumab PET. A side study to the phase I-II study with AUY922 in either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101.

Imaging the effect of HSP90 inhibitor AUY922 on HER2 expression by means of 89Zr-trastuzumab PET. A side study to the phase I-II study with AUY922 in either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101. - 89Zr-trastuzumab PET for imaging the effect of HSP90 inhibition

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33851

Enrollment

Registered

2009-09-14

Start date

2010-02-19

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer mammary carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - patients with HER2 positive, trastuzumab (and lapatinib) refractory breast cancer - participation in the phase I-II trial with HSP90 inhibitor AUY922 (in- and exclusion criteriafor this study with AUY922 are described in protocol CAUY922A2101 -METc 2008.237- section 5.1 and 5.2 (p 37-40).

Exclusion criteria

Exclusion criteria: - no participation in the phase I-II trial with HSP90 inhibitor AUY922

Design outcomes

Primary

Measure	Time frame
Measurement of decreased HER2 expression compared to baseline, as a reflection of response to HSP90 inhibitor AUY922. A decline is defined as at least a 30% decrease of the mean SUV in a maximum of three lesions. These lesions will have a size of at least 2 cm (on the baseline CT), and will show the highest uptake on baseline 89Zr-trastuzumab scan (on which they are predefined).	—

Countries

Netherlands

Outcome results